Literature DB >> 23970502

Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes.

H Kang1, L M Metz, A L Traboulsee, M Eliasziw, G J Zhao, Y Cheng, Y Zhao, D K B Li.   

Abstract

BACKGROUND: The 2005 and 2010 McDonald criteria utilize magnetic resonance imaging (MRI) to provide evidence of disease dissemination in space (DIS) and time (DIT) for the diagnosis of multiple sclerosis (MS) in patients who have clinically isolated syndromes (CIS).
METHODS: Data from 109 CIS patients not satisfying the 2005 criteria at entry into a randomized controlled minocycline trial were analyzed to determine the proportion who would have been diagnosed with MS at screening based on 2010 criteria. The impact of including symptomatic, as well as asymptomatic, MRI lesions to confirm DIT was also explored.
RESULTS: Thirty percent (33/109) of patients, retrospectively, met the 2010 criteria for a diagnosis of MS at baseline. When both symptomatic and asymptomatic lesions were used to confirm DIT, three additional patients met the 2010 criteria. There was a significant 10.1% increase in the proportion of patients who met the 2010 DIS criteria, compared with the 2005 DIS criteria; however, two patients satisfied the 2005 DIS but not 2010 DIS criteria.
CONCLUSION: Using 2010 McDonald criteria, 30% of the CIS patients could be diagnosed with MS using a single MRI scan. Inclusion of symptomatic lesions in the DIT criteria further increases this proportion to 33%.

Entities:  

Keywords:  Magnetic resonance imaging (MRI); McDonald criteria; clinically isolated syndromes (CIS); diagnostic criteria; multiple sclerosis (MS)

Mesh:

Substances:

Year:  2013        PMID: 23970502     DOI: 10.1177/1352458513501230

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

2.  High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.

Authors:  Simon Gamraoui; Guillaume Mathey; Marc Debouverie; Catherine Malaplate; René Anxionnat; Francis Guillemin; Jonathan Epstein
Journal:  J Neurol       Date:  2019-02-01       Impact factor: 4.849

3.  Should the symptomatic region be included in dissemination in space in MRI criteria for MS?

Authors:  Wallace J Brownlee; Josephine K Swanton; Katherine A Miszkiel; David H Miller; Olga Ciccarelli
Journal:  Neurology       Date:  2016-07-15       Impact factor: 9.910

Review 4.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

5.  Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.

Authors:  A Traboulsee; J H Simon; L Stone; E Fisher; D E Jones; A Malhotra; S D Newsome; J Oh; D S Reich; N Richert; K Rammohan; O Khan; E-W Radue; C Ford; J Halper; D Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-11-12       Impact factor: 3.825

Review 6.  MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Authors:  Massimo Filippi; Maria A Rocca; Olga Ciccarelli; Nicola De Stefano; Nikos Evangelou; Ludwig Kappos; Alex Rovira; Jaume Sastre-Garriga; Mar Tintorè; Jette L Frederiksen; Claudio Gasperini; Jacqueline Palace; Daniel S Reich; Brenda Banwell; Xavier Montalban; Frederik Barkhof
Journal:  Lancet Neurol       Date:  2016-01-26       Impact factor: 44.182

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.